å»è¬åå ¬è¡šãããæŽå¯
泚å°å¯èœãªè¬å€ã®é éã·ã¹ãã ã¯ããã£åœ¢æãç®ã®ãã€ãç· ãŸãããšããã³ããã®åŠçœ®ã®ãããªå¯©çŸçãªåŠçœ®ã«äœ¿çšãããŸãã æ°ããªæ²»çæ³ã®éžæè¢ãšããŠãå»çæè¡ã®é²æ©ãšããŠãçèå ãéèå ãããã³ç®äžã®ãããªæ£è ã®äœã«å ¥ãããã®ããŸããŸãªç®¡çã«ãŒãããããŸãã ããã€ãã®æçç©è³ªãæ¶²äœè¬ãããã³ç¡¬åäºé²æ¥çš®ã®ç ç©¶ãšéçºã®ãã ã¢ã¯ã»ãµãªãŒ é«åºŠãªå»çæè¡ã«å€§ããªæè³ãããŠããŸããç±³åœé£åå»è¬åå±ã«ãããšãè¬ç©ããã³ã¯ã¯ãã³ã®97%ã¯æ³šå°ãéããŠæäžãããã äž»èŠãªæ³šå°è¬ã¯ãã©ãžã«ã®remicadeãavastinãneulastaãrituxanãçãå«ãã§ããŸãããã©ãžã«ã®æ³šå°è¬ã¯ãç é¢ãè¡ç®¡ã®æ§æ... ãã£ãšèŠã
ãããã©ãããŒã«åžå Žã補åã¿ã€ãå¥ïŒå³ææŸåºåãããã©ãããŒã«ãåŸæŸæ§ïŒåŸæŸïŒãããã©ãããŒã«ã泚å°çšãããã©ãããŒã«ïŒãçšé匷床å¥ïŒ20 ïœ 40 mgã60 ïœ 80 mgã10 mg ãŸã§ãããã³ 100 mg 以äžïŒãé©å¿çå¥ïŒé«è¡å§ãçå¿çã äžæŽèãçé çã®äºé²ãäžå®é害ïŒããã©ãŒãã³ã¹/ç€ŸäŒæ§ïŒãç²ç¶è ºæ©èœäº¢é²ç/ç²ç¶è ºäžæ¯çãæ¬æ æ§æ¯æŠãä¹³å è¡ç®¡è «ãå¿çæ¢å¡åŸã®ç®¡çãããã³ãã®ä»ã®å¿è¡ç®¡çŸæ£ïŒãæ£è 人å£çµ±èšå¥ïŒå°å ãæäººãé«éœ¢è ïŒãæµéãã£ãã«å¥ïŒç é¢ã®è¬å±ãå°å£²ïŒ è¬å±ããªã³ã©ã€ã³è¬å±ãæ¿åºæ©é¢ããã³æ©é¢ã®äŸçµŠïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ãå°éã¯ãªããã¯ïŒå¿èç ç§ãç¥çµå ç§ãå ... ãã£ãšèŠã
ã ããã·ã³è»èåžå Žã補åã¿ã€ãå¥ïŒ2ïŒ è»èã2ïŒ ã¯ãªãŒã ããã®ä»ã®å±æè£œå€ïŒãçšéå¥ïŒç®èææçæ²»çïŒè¿çç¹ãæ¯å¢çãæ¹¿ç¹é¢é£ææçïŒãåµå·ã±ã¢ïŒåãå·ãæŠãå·ãæè¡éšäœã®ææçïŒãç«å·ããã®ä»ïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ã蚺çæãå°å£²è¬å±ã ãªã³ã©ã€ã³è¬å±ã倿¥èšºçã»ã³ã¿ãŒ)ãæµéãã£ãã«å¥ (ç é¢è¬å±ãå°å£²è¬å±ãé»ååååŒ / ãªã³ã©ã€ã³è¬å±)ãå°çå¥ (åç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
ã³ã«ãã£ã»ãã»ã·ã³ãã·ã¹ãšã³ã«ãã£ãã¹ã»ããªã¿ãªãŒã¹ã¯ãæ°å€ãã®å¥åº·äžã®å©ç¹ãæã€ãå¯çèçš®ãšæ»ãã ã«ã»ã«ãã©ãŒã§ãã äœãå é€ãå«ãçŽ21ã®ç æ°ã®ããã®åŠçœ®ãšããŠãé«ã䜿çšãããŸãã è¡å§ãçãäŒçµ±çãªäžåœå»åŠããã³ããããã®è¬ã§ã çãã幌è«ã¯ã幌è«ã®äœå ã§æé·ãããããææããè æã®èåã®çµæãšããŠåå£ã«ãã£ãããšåè§£ãããmummifiedãããŸãã åœç¶ã®ããšãªãããã³ã«ãã£ãã¹ã»ã¹ãã ã¯ãã«ã¬ã«ãã©ãŒã®é ããçºå±ããŠããŸããäžççãªã³ã«ãã£ã»ãSinensisãšMilitarisãšãã¹åžå Ž - ã³ãããŠã€ã«ã¹ã®åœ±é¿(COVID-19)ãã³ãããã¯ã³ãããŠã€ã«ã¹(COVID-19)çº... ãã£ãšèŠã
è žããã¹ãšãåŒã°ããè žããã¹ã¯ããµã«ã¢ãã©è žçèïŒSalmonella enterica serotype TyphiïŒã«ãã£ãŠåŒãèµ·ããããçŽ°èææçã§ãããè žããã¹ã¯éåžžãæ±æãããé£ç©ãæ°Žã®æåã«ãã£ãŠåŒãèµ·ãããããè žããã¹ã¯ã¯ãã³ã¯è žããã¹ãäºé²ããè žããã¹ãã身ãå®ããŸããäžçä¿å¥æ©é¢ïŒWHOïŒã¯ã匱æ¯çã¯ã¯ãã³ãè¢èå€ç³äœã¯ã¯ãã³ãçµååã¯ã¯ãã³ã®3çš®é¡ã®è žããã¹ã¯ã¯ãã³ã®äœ¿çšãæšå¥šããŠããã äžçã®è žããã¹ã¯ã¯ãã³åžå Žã¯ã2022幎ã«ã¯3å5,140äžç±³ãã«ãšæšå®ãããäºæž¬æéäžïŒ2022-2030幎ïŒã«12.2 %ã®CAGRã瀺ããšäºæž¬ãããŠããã å³1. è žããã¹ã¯ã¯ã... ãã£ãšèŠã
ã³ãŒãã£ã³ã°é åžå Žãã³ãŒãã£ã³ã°ã¿ã€ãå¥ïŒãã£ã«ã ã³ãŒãã£ã³ã°é ãç³è¡£é ãè žæº¶é ãå§çž®ã³ãŒãã£ã³ã°é ããŒã©ãã³ã³ãŒãã£ã³ã°é ïŒãã³ãŒãã£ã³ã°ææå¥ïŒé«ååã³ãŒãã£ã³ã°ãç³ã³ãŒãã£ã³ã°ãã»ã«ããŒã¹ã³ãŒãã£ã³ã°ãã¢ã¯ãªã«ç³»ã³ãŒãã£ã³ã°ã倩ç¶ã³ãŒãã£ã³ã°ïŒãæ©èœç®çå¥ïŒéæŸæ§ã³ãŒãã£ã³ã°ã é å»¶æŸåºã³ãŒãã£ã³ã°ãåŸæŸæ§/æŸåºå¶åŸ¡ã³ãŒãã£ã³ã°ãå³ãã¹ãã³ã°ã³ãŒãã£ã³ã°ãããã³æ¹¿æ°ããã³å ä¿è·ã³ãŒãã£ã³ã°ïŒãæ²»ççšéå¥ïŒå¿èè¡ç®¡è¬ãèè žè¬ãæææçè¬ãCNSè¬ãé®çè¬ããã¿ãã³ããã³æ é€è£å©é£åããã®ä»ïŒåŒåžåšè¬ãæç³å°¿ç è¬ãªã©ïŒïŒããšã³ããŠãŒã¶ãŒå¥ïŒè£œè¬ã¡ãŒã«ãŒã æ é€è£å©é£åã¡ãŒã«ãŒãåèšè£œé çµç¹ ... ãã£ãšèŠã
çã¯ã¯ãã³åžå Žãã¯ã¯ãã³ã¿ã€ãå¥ïŒæ··åïŒå€äŸ¡ïŒã¯ã¯ãã³ãäžæŽ»åïŒäžæŽ»åïŒã¯ã¯ãã³ã匱æ¯åçã¯ã¯ãã³ãçµæãã¯ã¯ãã³ããããœã€ãã¯ã¯ãã³ãDNA/ãã¯ã¿ãŒããŒã¹ã¯ã¯ãã³ïŒãçŸæ£é©å¿çå¥ïŒãŠã·åŒåžåšçŸæ£ïŒBRDè€åäœãIBRãBRSVãPI3ïŒãå£è¹ç«ïŒFMDïŒãã¯ãã¹ããªãžãŠã çŸæ£ïŒé»èç ãè žæ¯çŽ è¡çã ç Žå·é¢šïŒããŠã·ãŠã€ã«ã¹æ§äžç¢ïŒBVDïŒãã¬ããã¹ãã©çãä¹³æ¿çããã«ã»ã©çãççœç ããã®ä»ïŒãšãŒãç ããã«ãŒã¿ã³ã°ãªã©ïŒïŒãçã®çš®é¡å¥ïŒä¹³çãèçãç¹æ®çãããã³åç/è¥ãçïŒãæäžçµè·¯å¥ïŒæ³šå°ã¯ã¯ãã³ãçµéŒ»ã¯ã¯ãã³ãçµå£ã¯ã¯ãã³ïŒããšã³ããŠãŒã¶ãŒå¥ïŒåçšïŒ é ªèŸ²å Žãé€çå Žãšç§å Žãåç©ç é¢ãšç é¢... ãã£ãšèŠã
å»çã®é£äºã¯ãæ§ã ãªç æ°ã«èŠããã§ããäººãæ²»ãå¯äžã®ç®çã®ããã«äœãããã«ã¹ã¿ã ã¡ã€ãã®æ¶²äœãœãªã¥ãŒã·ã§ã³ã§ãã æ§ã ãªç æ°ã«èŠãã人ã ã«ãã¶ã€ã³ãããé£äºãæäŸããŸãã ååãªæ é€çŽ ãæ£è ã«æäŸããç¹å¥ã«æºåãããé£äºçæ³ã§ãã å°å æ é€ãšç£çãã代è¬ã®èª€ããæ²»çããããã«ãå»åŠçé£äºãäœæãããŸããããŸããŸãªææšã®ããã®å€æ§ãªè£œåããŒããã©ãªãªãæã€Abbottãªã©ã®äŒæ¥ã¯ãå»çé£ååžå Žããã£ããææ¡ããå€ãã®äºæ¥é åãéããŠäžè²«ããåçãçæã§ããŸãã ã¡ãŒã«ãŒã¯ãæ°ããç æ°ã®é©å¿ã®ããã®è£œåãéçºããŠããŸãã, å»çé£ååžå Žã®çææé·. å»çé£åã¯ãç¹å®ã®ç æ°ã«èŠãã人ã ã®æ é€ãšä»£è¬ã®... ãã£ãšèŠã
ãã©ã³ãŒãæ²»çåžå Žãæ²»çã¿ã€ãå¥ïŒæçç©è³ªïŒçµå£æçç©è³ªããã³å±ææçç©è³ªïŒãå€ç§çåŠçœ®ïŒãã©ã³ãŒãæ§ç«æ¯çïŒTTïŒæè¡ããŸã€ãé€å»ïŒè±æ¯ãªã©ïŒïŒãé¡ã®æž æœãšè¡çïŒè¡çãããããã³å ¬è¡è¡çãã£ã³ããŒã³ïŒïŒã補å€å¥ïŒçµå£é å€ãçµå£æžæ¿æ¶²ãå±æïŒ è»èãæ³šå°å€ãããã³åŸæŸæ§/çŒçšã€ã³ãµãŒãïŒç ç©¶éçºæ®µéïŒïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ã蚺çæãè¬å±ãå ¬è¡è¡çæ©é¢ïŒãçŸæ£æ®µéå¥ïŒæŽ»åæ§ãã©ã³ãŒãããã©ã³ãŒãæ§ç«æ¯çãç¢çæ§ç¢çïŒãæµéãã£ãã«å¥ïŒãªã³ã©ã€ã³ããã³ãªãã©ã€ã³ïŒãå°çå¥ïŒåç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«ïŒ... ãã£ãšèŠã
å€åœ¢æ§é¢ç¯çãšãåŒã°ãããªã¹ããªã¢ã«ãããã¯ãé¢ç¯çã®æãäžè¬çãªåœ¢æ ã§ãã äœå ã®æ§ã ãªé¢ç¯ã«åœ±é¿ããŸãã ããããç æ°ã¯èãéŠãè °ãè °ãæã®å°ããªé¢ç¯ã«å€§ããªåœ±é¿ãäžããŸãã Osteoarthritisã¯ãé¢ç¯çŸæ£ã®äž»èŠãªè¡°åŒ±åœ¢æ ã§ãããããæ¶å管ã®äººå£ã§æããã§ãã ç æ°ã¯äœäœååŠçããã»ã¹ã§ãããçæŽ»ã®è³ªãæ©èœã®åªå€±ãããã³é床ã®çã¿ã«é©åºŠã«ã€ãªãããç¹ã«äœäœæŽ»åãé«äœè³ªéææ°(BMI)ãæã€äººå£ã§ã Osteoarthritisã¯è»éªšã®å±æçãªæå€±ã«ãã£ãŠç çåŠçã«ç¹åŸŽä»ããããŸãã飿¥ãã骚ããã³é¢é£ã®ççã®æ¹é ã æ§ã ãªãã©ãŠãã¯ãé¢ç¯ã®å¿ èŠæ§ãããªã¬ãŒããŠä¿®åŸ©ããããšãã§ããŸ... ãã£ãšèŠã
ãã»ããŠç åžå ŽãçŸæ£ã¿ã€ãå¥ïŒé¡æ§ãã»ããŠç ããã³æœåšæ§ãã»ããŠç ïŒãçç¶å¥ïŒç²ç¶è ºäžæ¯çããã»ããŠçŒçª©çïŒçŒïŒãç®èé害ïŒåèéªšç²æ¶²æ°Žè «ïŒããã®ä»ã®å šèº«çç¶ïŒãèšºææ¹æ³å¥ïŒèšåºè©äŸ¡ãç»å蚺æïŒè¶ 鳿³¢ãæŸå°æ§ãšãŠçŽ åã蟌ã¿ã¹ãã£ã³ãMRI/CTïŒïŒ çŒçª©çŸæ£))ãæ€æ»å®€(TSHãéé¢T3/éé¢T4ãTSHåå®¹äœæäœ(TRAb)))ãæ²»çæ³å¥(è¬çåŠç(æç²ç¶è ºè¬(ã¡ãããŸãŒã«ããããã«ããªãŠã©ã·ã«ãã«ã«ãããŸãŒã«)ãÎ²é®æè¬ãã³ã«ãã³ã¹ããã€ããå ç«æå¶è¬)ãæŸå°æ§ãšãŠçŽ çæ³ãå€ç§ç(ç²ç¶è ºå šæè¡) ããã³ç²ç¶è ºäºå šæè¡ïŒãè£å©ç/çŒç§ïŒçŒçª©æžå§è¡ããªããã·ãããããã³ããããã ããïŒãããã³... ãã£ãšèŠã
ãªã³é žã¯ãªã³ããã€ã·ã³åžå Žã補å€ã¿ã€ãå¥ïŒå±æãžã§ã«ãçµå£ã«ãã»ã«ãçµå£æ¶²å€ã泚å°å€ïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ãã¯ãªããã¯ãå°å£²è¬å±ããªã³ã©ã€ã³è¬å±ïŒãçšéå¥ïŒãããæ²»çã骚ããã³é¢ç¯ææçãè»éšçµç¹ææçãæ°éææçã骚ç€ççæ§çŸæ£ããã®ä»ïŒäŸïŒ å¿å èç))ãæµéãã£ãã«å¥ (ãªã³ã©ã€ã³ããã³ãªãã©ã€ã³)ãå°çå¥ (åç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãããã³ã¢ããªã«)... ãã£ãšèŠã
Budesonideã¯åæ¯ã®åŸŽåãé²ãã®ã«äœ¿çšãããŠããè¬ã§ãã ããã¯ã³ã«ãã³ã¹ããã€ããŸãã¯ã¹ããã€ã(ã³ã«ããŸã³æ§è¬)ã§ãã è¬ç©ã¯èºã®ççãé²ããåæ¯ã®æ»æã®éç床ãäœäžãããŸãã åžå ¥ããŒãœããã¯ãèºã®çãåŒåžéè·¯ãéãããã«äœ¿çšãããæ°ç®¡æ¯æ¡åŒµå€ãªã©ã®ä»ã®åæ¯è¬ã§äœ¿çšããããšãã§ããŸãã ç²æ«ããµã¹ãã³ã·ã§ã³ãé å€ãªã©ã®ããã€ãã®åœ¢æ ã§Buesonideãå©çšå¯èœã§ãã ç²æ«åœ¢æ ã§ã¯ãåžå ¥å€ã䜿çšããŠå£ã§åžå ¥ããããšãã§ããŸãã ãŸããç¹å¥ãªãžã§ããããã©ã€ã¶ãŒ(åžå ¥å¯èœãªãã¹ãã«è¬ãåãæ©æ¢°)ã䜿çšããŠãå£ããåžå ¥ããæžæ¿æ¶²ãšããŠäœ¿çšããããšãã§ããŸãã ããã§ãœããã販売ãããŠ... ãã£ãšèŠã
ã¿ã¯ããªã ã¹ã¯ãè ç§»æ€ãåããäººã®æçµ¶åå¿ïŒã¬ã·ããšã³ãã®å ç«ç³»ã«ããç§»æ€èåšã®æ»æïŒãäºé²ããããã«ãä»ã®è¬å€ãšäœµçšãããŸããã¿ã¯ããªã ã¹ã¯ãŸããèèãèºããŸãã¯å¿èç§»æ€ã®ã¬ã·ããšã³ãã«ãããæçµ¶åå¿ãäºé²ããããã«ãä»ã®è¬å€ãšäœµçšãããŸããã¿ã¯ããªã ã¹ã¯å ç«æå¶è¬ãšããŠç¥ãããè¬å€ã®äžçŸ€ã«å±ãããã¿ã¯ããªã ã¹ã¯ãç§»æ€èåšã«å¯Ÿããå ç«ç³»ã®æ»æãé²ãããã«ãå ç«ç³»ã®æŽ»åãæå¶ããããšã«ãã£ãŠäœçšããã ã¿ã¯ããªã ã¹ã®äžçåžå ŽèŠæš¡ã¯2022幎ã«64å8,530äžç±³ãã«ãšæšå®ãããäºæž¬æéïŒ2022ïœ2030幎ïŒã®å¹Žå¹³åæé·ç㯠4.7 ïŒ ãšäºæ³ãããŠããã å³1.ã¿ã¯ããªã ã¹ã®äžçåžå Žã·ã§ã¢... ãã£ãšèŠã
ãžã§ããªãã¯å»è¬ååžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033äžççãªãžã§ããªãã¯å»è¬ååžå Žã¯ã2026幎ãã2033幎ãŸã§çå®ã«æé·ããç¹èš±ã®æŸåãšå¢å ãããã«ã¹ã±ã¢éèŠã«ãã£ãŠæšé²ãããŠããŸãã 2026幎ã«çŽ480åç±³ãã«ã«çžåœãã2033幎ãŸã§ã«çŽ720åç±³ãã«ã«éããèŠèŸŒã¿ã§ãçŽ6.3%ã®ååç©å¹Žéæé·ç(CAGR)ã®ç»é²ãé²ãã§ããŸãããããã£ãŒã«ãžã§ããªãã¯å»è¬åã¯ãé©éã匷床ãå®å šæ§ãåè³ªãæ§èœãããã³æå³ããã䜿çšã«ããããã©ã³ãã®è¬ã«çžåœããããã«èšèšãããŠããŸãã ãããã¯éæã®è¬å€ã®æå¹æéãåãããããçŸå®çãªåŠçœ®ã®éžæãæäŸããããã³ãã®ä¿è·ã®åŸã§æ®éå°å ¥ãããŸãã ... ãã£ãšèŠã
Hemophiliaã¯ãæ£è ã®è¡æ¶²ãååºå åãšããŠç¥ãããŠããè¡æŒ¿ã¿ã³ãã¯è³ªã®æ¬ åŠã®ããã«ãéåžžã¯è æããªãéºäŒåé害ã§ãã æ £ç¿çãªåŠçœ®ã®éžæã¯ç¹å®ã® clotting ã®èŠå ã®ææ©ãåŸãåãæ¿ããå«ãã§ããŸãã 倧æè¬å±ããã€ãªãã¯ãããžãŒäŒæ¥ã¯ãåŸæ¥ã®æ²»çãšæ§ã ãªæ¬ ç¹ã«ãããè¡åç ã®éºäŒåæ²»çãéçºããããã«ç ç©¶éçºãè¡ã£ãŠããŸãã æ²»çããã³åŒ·åãªè£œåãã€ãã©ã€ã³ãå¿ èŠãšããå€ãã®è¡åç æ£è ã®å¢å ã¯ãè¡åç éºäŒåæ²»çåžå Žã®æé·ãä¿é²ããããšãæåŸ ãããŸããäžççãªè¡åç éºäŒåæ²»çåžå Žã¯ãè©äŸ¡ããããšæšå®ããã US$ 330.9 çŸäž ãåãåãã 2022幎 å±ç€ºäºå® ã«ã°ã¬ ã«ã€ã... ãã£ãšèŠã
ãšãªã»ãªãªãŒãšåœç€Ÿã«ãããã©ã³ãåAlimtaã§è²©å£²ãããŠããPemetrexedã¯ãpleural mesotheliomaããã³éå°çްèèºçã®æ²»çã®ããã«ç€ºãããååŠçæ³è¬ã§ãã Alimtaã¯èé žã®ã¢ããã°ã®æ°é³ä»£è¬æå¶å€ã§ãããããŸããŸãªç æ°ã®ããã«ç€ºãããç¹å®ã®è¬å€ãšã®çµåãã§:屿é«åºŠãŸãã¯è»¢ç§»éæ°Žééå°çްèèºç(NSCLC)ã®æ£è ã®åææ²»çã®ããã®ã·ã¹ãã©ãã³ãšçµã¿åãããŠå±æçãªé«åºŠãŸãã¯è»¢ç§»ã®éæ°Žééå°çްèèºç(NSCLC)ã®æ£è ã®ç¶æãããŠåŠçœ®ã®ããã®åäžã®ä»£çåºãšããŠããã®ç æ°ã¯ãã©ãã ããŒã¹ã®ç¬¬äžç·ååŠçæ³ã®4ã€ã®åšæã®åŸã§é²æ©ããªãã£ãååŠçæ³ã®åŸã®åçºè»¢ç§»ã®éæ°Žé... ãã£ãšèŠã
ã¯ã¯ãã³åèšè£œé åžå ŽèŠæš¡ãšäºæž¬ - 2026幎ïœ2033幎ã°ããŒãã«ã¯ã¯ãã³åèšè£œé åžå Žã¯ã 2026幎ã®USD 3.0åãçŽUSD 6.3ã«éããèŠèŸŒã¿ 2033幎ãŸã§ã«ãååç©ã®å¹Žéæé·ç(CAGR)ã衚ã 2026幎ãã2033幎ã«ãããŠçŽ8.45 %ããããã£ãŒã«ã¯ã¯ãã³åèšè£œé ãšã¯ãã¯ã¯ãã³ã®å§èšã«ã€ã㊠éçºãçç£ãé åãå å¡«ãå è£ ããã³å質 å°éã®ç¬¬äžè ã®è£œé æ¥è ãžã®ãã¹ãã å»è¬åã»å»è¬å ãã€ãªãã¯ãããžãŒäŒæ¥ã¯ãåèšéçºã»è£œé ãè¡ã£ãŠããŸãã è³æ¬æè³ãåæžããå éããçµç¹(CDMO) ã¿ã€ã ã»ããŒã»ããŒã±ãããããã³é«åºŠã®æè¡ã«ã¢ã¯ã»ã¹ããŠäžããã ãµãŒãã¹ã«ã¯ãŠã€ã«ã¹... ãã£ãšèŠã